Voyager Therapeutics, Inc.
VYGR
$3.24
-$0.16-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -19.07% | -45.50% | -49.53% | -80.88% | -70.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.07% | -45.50% | -49.53% | -80.88% | -70.38% |
| Cost of Revenue | -9.81% | -3.06% | 5.93% | 16.75% | 16.28% |
| Gross Profit | 5.22% | -42.53% | -104.83% | -311.29% | -360.07% |
| SG&A Expenses | -13.97% | -5.11% | 1.46% | 0.15% | 0.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.74% | -3.51% | 4.93% | 12.69% | 12.21% |
| Operating Income | 7.87% | -24.80% | -58.87% | -1,311.33% | -2,871.99% |
| Income Before Tax | -0.32% | -38.70% | -85.86% | -570.68% | -1,205.04% |
| Income Tax Expenses | -81.44% | -82.41% | -78.35% | -20.38% | -0.59% |
| Earnings from Continuing Operations | 0.19% | -37.72% | -84.18% | -589.88% | -1,296.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.19% | -37.72% | -84.18% | -589.88% | -1,296.21% |
| EBIT | 7.87% | -24.80% | -58.87% | -1,311.33% | -2,871.99% |
| EBITDA | 7.81% | -26.59% | -63.41% | -918.94% | -16,744.55% |
| EPS Basic | 2.07% | -35.63% | -81.30% | -388.61% | -683.06% |
| Normalized Basic EPS | 4.80% | -36.59% | -84.84% | -364.67% | -589.20% |
| EPS Diluted | 2.16% | -34.96% | -79.74% | -404.34% | -755.75% |
| Normalized Diluted EPS | 4.80% | -36.59% | -84.84% | -375.32% | -633.94% |
| Average Basic Shares Outstanding | 2.12% | 1.73% | 1.77% | 7.90% | 14.88% |
| Average Diluted Shares Outstanding | 2.12% | 1.73% | 1.77% | 7.36% | 14.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |